Abstract 1278: Differenzielles Harnmikrobiom und dessen metabolischer Fußabdruck bei Blasenkrebspatienten nach BCG-Behandlung

Piao et al. (Fr,) untersuchten diese Fragestellung.

www.synapsesocial.com/papers/68e72ce8b6db6435876a6fcf — DOI: https://doi.org/10.1158/1538-7445.am2024-1278

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Abstract B018: Gut microbiome influences the antitumor response to BCG immunotherapy in bladder cancer· 2025
2. Changes of urinary immunity and microbiome after intravesical BCG therapy and their association with outcomes in NMIBC· 2026
3. Abstract PR004: Spatial proteomics and transcriptomics reveal an altered immune cell landscape in bladder cancer patients unresponsive to BCG treatment· 2024
4. Abstract B017: Impact of gut microbiota on response to Bacillus Calmette-Guérin immunotherapy in bladder cancer: Towards a predictive molecular model· 2025
5. Abstract PR-08: Impact of gut microbiota on response to Bacillus Calmette-Guérin immunotherapy in bladder cancer: Towards a predictive molecular model· 2025